Centrus prices roughly $500 million equity and warrants offering

Centrus Energy (NYSE: LEU) expects approximately $500 million in gross proceeds from an offering of Class A common stock and warrants, according to its September 11 Form 8-K, accession number 0001104659-26-107103. The financing pairs an initial capital raise with common warrants that could bring additional equity issuance and cash if exercised.

A $500 million financing with several components

Centrus entered an underwriting agreement on September 9 with Guggenheim Securities, LLC, acting as representative of the underwriters. The offering covers 500,000 shares of Class A common stock, pre-funded warrants to purchase up to 2,005,513 Class A shares, and common warrants to purchase up to 6,992,382 Class A shares. The common stock has a par value of $0.10 per share. These terms appear in Item 1.01 of the company's September 11 Form 8-K.

The scale of the expected gross proceeds makes this a significant financing for the covered industrials company. But the transaction has several distinct components: shares sold directly, shares available through pre-funded warrants, and shares available through four series of common warrants. Those distinctions matter when assessing both the initial financing and the possibility of additional shares being issued later.

The approximately $500 million figure is expected gross proceeds before underwriting discounts and offering expenses. It is not a net cash figure, and it should not be combined with potential common-warrant exercise proceeds as though all of that money has already been raised.

Pricing and the pre-funded alternative

The combined public offering price is $199.64 for each Class A share and its accompanying common warrants. For each pre-funded warrant and its accompanying common warrants, the combined price is $199.54, according to the pricing release included as Exhibit 99.2. Although the prices include accompanying common warrants, the shares and warrants are issued separately, rather than as a unit.

The pre-funded warrants carry an exercise price of $0.10 per share. They are exercisable immediately and remain exercisable through the 25-year anniversary of issuance. Their purchase price is therefore distinct from the small additional payment required to exercise them. The warrant forms specify September 11, 2026, as the date of issuance; the terms are described in Item 1.01 and the pre-funded warrant form.

The dates also separate the financing agreement from the filing that disclosed it. The underwriting agreement is dated September 9, while the Form 8-K was filed September 11. Item 7.01 identifies both a launch release and a pricing release dated September 9. Those releases were furnished, rather than filed, under that item.

Four common-warrant exercise prices

The common warrants span four series, with per-share exercise prices of $226.8625, $272.2350, $317.6075 and $362.9800. Each series has an aggregate exercise price of approximately $500 million, or approximately $2 billion across all four series, according to Item 1.01 and the common warrant form.

That approximately $2 billion describes the aggregate exercise price associated with the common warrants. It is separate from the approximately $500 million in expected gross offering proceeds. The existence of the warrants does not establish that holders will exercise them or that Centrus will receive the full aggregate exercise amount.

For shareholders, the structure creates a distinction between the initial financing and potential subsequent equity issuance. The 500,000 shares are the direct stock component; the pre-funded and common warrants provide rights to acquire additional shares under their respective terms. The financing's eventual share count and cash effects therefore depend in part on warrant exercise, rather than on the headline offering amount alone.

Closing, commissions, and use of proceeds

The closing of the offering is expected to occur on or about September 11, 2026, subject to the satisfaction of customary closing conditions. Underwriting commissions are $3.9928 per Share and $3.9908 per Pre-Funded Warrant on the Closing Date; the filing states no underwriting commissions on the Common Warrants on the Closing Date. Net proceeds are intended for general working capital and corporate purposes, which may include technology development and deployment, debt repayment or repurchase, capital expenditures, and potential acquisitions, without disclosed allocation amounts.

Manufacturing acquisition remains a possibility

Separately, Item 8.01 says Centrus is in advanced discussions about potentially acquiring an existing domestic manufacturing supplier. The anticipated purchase price is approximately $115 million to $125 million. The prospective target generated approximately $160 million in revenue for the year ended December 31, 2025, according to the 8-K disclosure.

No definitive agreement has been reached. The potential transaction remains subject to definitive documentation, diligence, approvals, closing conditions and board approval, and Centrus gives no assurance that it will be completed. These are discussions about a possible purchase, not an announced completed acquisition.

The acquisition disclosure provides context alongside the financing, but it does not establish a completed use of the offering proceeds. The concrete developments in this filing are the underwriting agreement and the disclosed offering terms; the manufacturing transaction remains contingent. This financing is also distinct from Centrus's earlier Radiant HALEU supply agreement story.